NASDAQ:VIVO - Meridian Bioscience Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Meridian Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $7.45 -0.36 (-4.61 %) (As of 02/26/2020 08:13 AM ET) Add Compare Today's Range$7.35Now: $7.45▼$7.8350-Day Range$7.45MA: $9.05▼$11.5052-Week Range$7.35Now: $7.45▼$17.71Volume610,603 shsAverage Volume585,901 shsMarket Capitalization$319.08 millionP/E Ratio16.20Dividend YieldN/ABeta0.44 ProfileAnalyst RatingsAdvanced ChartDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Meridian Bioscience, Inc, a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for various gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms and technologies, including isothermal DNA amplification under the Alethia brand; rapid immunoassays, a single-use immunoassays under the ImmunoCard and ImmunoCard STAT! brand names; enzyme-linked immunoassays under the PREMIER brand; and anodic stripping voltammetry, an electrical chemical sensor platform for quantitative determination under the LeadCare brand. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Diagnostic substances Sub-IndustryHealth Care Supplies SectorMedical Current SymbolNASDAQ:VIVO Previous Symbol CUSIP58958410 CIK794172 Webhttp://www.meridianbioscience.com/ Phone513-271-3700Debt Debt-to-Equity Ratio0.38 Current Ratio4.37 Quick Ratio3.14Price-To-Earnings Trailing P/E Ratio16.20 Forward P/E Ratio21.91 P/E GrowthN/A Sales & Book Value Annual Sales$201.01 million Price / Sales1.59 Cash Flow$0.87 per share Price / Cash Flow8.53 Book Value$4.61 per share Price / Book1.62Profitability EPS (Most Recent Fiscal Year)$0.68 Net Income$24.38 million Net Margins9.70% Return on Equity13.02% Return on Assets7.97%Miscellaneous Employees585 Outstanding Shares42,830,000Market Cap$319.08 million Next Earnings Date5/5/2020 (Estimated) OptionableOptionable Receive VIVO News and Ratings via Email Sign-up to receive the latest news and ratings for VIVO and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:VIVO Rates by TradingView Meridian Bioscience (NASDAQ:VIVO) Frequently Asked Questions What is Meridian Bioscience's stock symbol? Meridian Bioscience trades on the NASDAQ under the ticker symbol "VIVO." How were Meridian Bioscience's earnings last quarter? Meridian Bioscience, Inc. (NASDAQ:VIVO) announced its quarterly earnings data on Friday, February, 7th. The company reported $0.10 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.06 by $0.04. The business had revenue of $47.42 million for the quarter, compared to analysts' expectations of $48.71 million. Meridian Bioscience had a return on equity of 13.02% and a net margin of 9.70%. View Meridian Bioscience's Earnings History. When is Meridian Bioscience's next earnings date? Meridian Bioscience is scheduled to release their next quarterly earnings announcement on Tuesday, May 5th 2020. View Earnings Estimates for Meridian Bioscience. What guidance has Meridian Bioscience issued on next quarter's earnings? Meridian Bioscience updated its FY 2020 Pre-Market earnings guidance on Friday, February, 7th. The company provided EPS guidance of 0.28-0.34 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.30. The company issued revenue guidance of $194.984-201.014 million, compared to the consensus revenue estimate of $198.54 million. What price target have analysts set for VIVO? 4 Wall Street analysts have issued 1 year price targets for Meridian Bioscience's shares. Their forecasts range from $8.00 to $14.00. On average, they expect Meridian Bioscience's share price to reach $11.00 in the next year. This suggests a possible upside of 47.7% from the stock's current price. View Analyst Price Targets for Meridian Bioscience. What is the consensus analysts' recommendation for Meridian Bioscience? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Meridian Bioscience in the last year. There are currently 1 sell rating and 3 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Meridian Bioscience. What are Wall Street analysts saying about Meridian Bioscience stock? Here are some recent quotes from research analysts about Meridian Bioscience stock: 1. According to Zacks Investment Research, "Meridian Bioscience, Inc. is a fully integrated life science company that manufactures, markets and distributes a broad range of innovative diagnostic test kits, purified reagents and biopharmaceutical enabling technologies that help deliver answers. Its products provide accuracy, simplicity and speed for the early diagnosis and treatment of common medical conditions, such as C. difficile, H. pylori, foodborne diseases and respiratory infections. In addition, the company develops and manufactures a variety of biological and non-biological materials used in proficiency testing programs. Meridian diagnostic products are used outside of the human body and require little or no special equipment. Meridian Bioscience designs their products to enhance the well-being of the patient-while reducing the total outcome costs of healthcare. Meridian has strong market positions in the areas of gastrointestinal infections, serology, parasitology and fungal disease diagnosis. " (11/3/2019) 2. Canaccord Genuity analysts commented, "We reiterate our SELL rating and $9 PT on VIVO. Third straight miss. FQ3/19 revs of $48.4M (-6% Y/Y) missed our/Street’s prior $49.8M (-4%), driven by broad-based weakness. Diagnostics declined 9% (vs. our -6%) driven by a ~21% decline in molecular ~15% decline in gastrointestinal revs (volume declines in 13% decline in H. Pylori revs due to price erosion). Life Science revs declined 0.3% due to softness in the 9% decline in molecular reagents. (-350bps) missed our 59%E. Meridian manufactured" an EPS beat based on lower investment and lower commissions paid to sales reps who missed their numbers. Adj. EPS of $0.16 beat our $0.07/Street’s $0.09. Third straight guide down." (7/31/2019) Has Meridian Bioscience been receiving favorable news coverage? News stories about VIVO stock have been trending somewhat positive recently, according to InfoTrie. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Meridian Bioscience earned a media sentiment score of 1.8 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the near term. View News Stories for Meridian Bioscience. Who are some of Meridian Bioscience's key competitors? Some companies that are related to Meridian Bioscience include Align Technology (ALGN), Cooper Companies (COO), West Pharmaceutical Services (WST), DENTSPLY SIRONA (XRAY), Haemonetics (HAE), ICU Medical (ICUI), Neogen (NEOG), Quidel (QDEL), Merit Medical Systems (MMSI), STAAR Surgical (STAA), Atrion (ATRI), Cerus (CERS), Anika Therapeutics (ANIK), Antares Pharma (ATRS) and OraSure Technologies (OSUR). What other stocks do shareholders of Meridian Bioscience own? Based on aggregate information from My MarketBeat watchlists, some companies that other Meridian Bioscience investors own include AbbVie (ABBV), Cara Therapeutics (CARA), Amicus Therapeutics (FOLD), Gilead Sciences (GILD), Canopy Growth (CGC), Amgen (AMGN), Exelixis (EXEL), Roku (ROKU), TherapeuticsMD (TXMD) and General Electric (GE). Who are Meridian Bioscience's key executives? Meridian Bioscience's management team includes the folowing people: Mr. John P. Kenny, CEO, Exec. VP of Diagnostics Bus. Unit & Director (Age 50)Ms. Susan D. Rolih, Consultant (Age 70)Ms. Melissa A. Lueke, Consultant (Age 56)Mr. Eric S. Rasmussen, Exec. VP & CFO (Age 51)Mr. Bryan Baldasare, Chief Accounting Officer, Sr. VP, Corp. Controller & Treasurer Who are Meridian Bioscience's major shareholders? Meridian Bioscience's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (7.67%), State Street Corp (3.73%), Geode Capital Management LLC (2.01%), Acadian Asset Management LLC (1.43%), Bank of New York Mellon Corp (1.30%) and Assenagon Asset Management S.A. (1.20%). Company insiders that own Meridian Bioscience stock include David Phillips, Dwight E Ellingwood, James M Anderson, John Mccune Jr Rice, John Mcilwraith, John P Kenny and Lawrence Baldini. View Institutional Ownership Trends for Meridian Bioscience. Which institutional investors are selling Meridian Bioscience stock? VIVO stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., AJO LP, Oxford Asset Management LLP, New York State Common Retirement Fund, Charles Schwab Investment Management Inc., Martingale Asset Management L P, Geode Capital Management LLC and Royce & Associates LP. View Insider Buying and Selling for Meridian Bioscience. Which institutional investors are buying Meridian Bioscience stock? VIVO stock was purchased by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Jacobs Levy Equity Management Inc., M&G Investment Management Ltd., Acadian Asset Management LLC, Assenagon Asset Management S.A., Russell Investments Group Ltd., AQR Capital Management LLC and Bank of Montreal Can. Company insiders that have bought Meridian Bioscience stock in the last two years include David Phillips, Dwight E Ellingwood, James M Anderson, John Mccune Jr Rice, John Mcilwraith and John P Kenny. View Insider Buying and Selling for Meridian Bioscience. How do I buy shares of Meridian Bioscience? Shares of VIVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Meridian Bioscience's stock price today? One share of VIVO stock can currently be purchased for approximately $7.45. How big of a company is Meridian Bioscience? Meridian Bioscience has a market capitalization of $319.08 million and generates $201.01 million in revenue each year. The company earns $24.38 million in net income (profit) each year or $0.68 on an earnings per share basis. Meridian Bioscience employs 585 workers across the globe.View Additional Information About Meridian Bioscience. What is Meridian Bioscience's official website? The official website for Meridian Bioscience is http://www.meridianbioscience.com/. How can I contact Meridian Bioscience? Meridian Bioscience's mailing address is 3471 RIVER HILLS DRIVE, CINCINNATI OH, 45244. The company can be reached via phone at 513-271-3700. MarketBeat Community Rating for Meridian Bioscience (NASDAQ VIVO)Community Ranking: 1.9 out of 5 ()Outperform Votes: 268 (Vote Outperform)Underperform Votes: 446 (Vote Underperform)Total Votes: 714MarketBeat's community ratings are surveys of what our community members think about Meridian Bioscience and other stocks. Vote "Outperform" if you believe VIVO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VIVO will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/26/2020 by MarketBeat.com StaffFeatured Article: What Are Cryptocurrencies?
